Skip to content

Equivalence trial of tribendimidine versus albendazole against hookworm infections in Ivory Coast

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN82278211
Enrollment
450
Registered
2006-01-24
Start date
2006-01-26
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hookworm infection (Necator americanus and Ancylostoma duodenale) Infections and Infestations Hookworm infection

Interventions

Intervention group: single oral dose of 400 mg tribendimidine Control group: single oral dose of 400 mg albendazole

Sponsors

Swiss Tropical Institute (Switzerland)
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Hookworm egg positive adult males (16-45 years) recruited at community survey in the region of Agboville (south Ivory Coast ) with written informed consent

Exclusion criteria

Exclusion criteria: 1. Any abnormal medical condition judged by the investigating medical team 2. Hypersensitivity to albendazole or any other anthelmintic drug 3. Taken any anthelmintic drug during the last month before enrolment 4. Hookworm egg negative after 4 Kato-Katz thick smears done on two consecutive stool specimens

Design outcomes

Primary

MeasureTime frame
1. Cure rate at 21 day post-administration 2. Egg reduction rate at 21 day post-administration 3. Observed acute adverse events within 1-3 hours and solicited adverse events within 24 hours

Secondary

MeasureTime frame
Rate of perceived illness episodes throughout the 6 months follow-up period with 1 week recall period

Countries

Cote d'Ivoire

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026